A cancer drug decades in the making significantly extended and improved the life of patients whose metastatic pancreatic cancer had stopped responding to previous treatments, researchers reported Sunday in The New England Journal of Medicine and at an American Society for Clinical Oncology meeting in Chicago. In a study of 500 last-stage pancreatic patients, those assigned Revolution Medicine’s daraxonrasib pill lived an average of 13.2 months versus 6.7 months for those undergoing chemotherapy. They also experienced fewer side effects.
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
